London, UK.
EMBO Rep. 2017 Dec;18(12):2101-2104. doi: 10.15252/embr.201745345. Epub 2017 Nov 9.
Novel therapies, such as gene or cell therapy, don not require radical changes of the regulatory framework for medicinal products. Yet, both new and old developments cannot be easily accommodated by existing regulations.[Image: see text]
新型疗法,如基因或细胞疗法,并不需要对药物监管框架进行重大改变。然而,新的和旧的发展都不能轻易被现有法规所容纳。[图片:见正文]